[{"data":1,"prerenderedAt":259},["ShallowReactive",2],{"$f7r7932zbwtty":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":21,"top_modalities":58,"top_diseases":82,"top_companies":113,"key_results":138,"trends":222,"previous_editions":231,"comparison":235,"highlighted_classes":256},1,"easd-2026","EASD","easd","EASD Annual Meeting 2026",2026,"Endocrinology & Metabolism","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},1410,511,121,{"Phase 1":17,"Phase 1\u002F2":4,"Phase 2":18,"Phase 4":19,"Phase 2\u002F3":4,"Phase 3":20},19,31,4,52,[22,26,30,34,38,41,45,48,52,55],{"name":23,"count":24,"share":25},"GLP1R",171,33,{"name":27,"count":28,"share":29},"INSR",72,14,{"name":31,"count":32,"share":33},"GIPR",56,11,{"name":35,"count":36,"share":37},"SGLT2",29,6,{"name":39,"count":40,"share":19},"AMY receptor",18,{"name":42,"count":43,"share":44},"ND1",16,3,{"name":46,"count":47,"share":44},"GCGR",15,{"name":49,"count":50,"share":51},"MR",10,2,{"name":53,"count":54,"share":51},"PPARA",8,{"name":56,"count":57,"share":4},"CALCR",7,[59,63,67,71,74,76,78,80],{"name":60,"count":61,"share":62},"Small molecules",220,43,{"name":64,"count":65,"share":66},"Peptides",193,38,{"name":68,"count":69,"share":70},"Non-antibody therapeutic proteins",116,23,{"name":72,"count":73,"share":57},"Monoclonal antibodies",34,{"name":75,"count":40,"share":19},"Oligonucleotide and RNA therapeutics",{"name":77,"count":47,"share":44},"Carbohydrate, lipid and polymer therapeutics",{"name":79,"count":54,"share":51},"Bispecific antibodies",{"name":81,"count":54,"share":51},"Cell therapies",[83,87,90,94,97,101,104,106,109,111],{"name":84,"count":85,"share":86},"type 2 diabetes mellitus (T2DM)",261,51,{"name":88,"count":89,"share":36},"obesity",147,{"name":91,"count":92,"share":93},"diabetes mellitus type 1 (T1D)",105,21,{"name":95,"count":96,"share":37},"Overweight",32,{"name":98,"count":99,"share":100},"insulin resistance (IR)",27,5,{"name":102,"count":103,"share":100},"chronic kidney disease (CKD)",24,{"name":105,"count":103,"share":100},"metabolic dysfunction-associated steatotic liver disease (MASLD)",{"name":107,"count":108,"share":19},"diabetes mellitus (DM)",20,{"name":110,"count":108,"share":19},"diabetic glomerulosclerosis",{"name":112,"count":47,"share":44},"metabolic dysfunction-associated steatohepatitis (MASH)",[114,117,120,123,125,127,129,132,134,136],{"name":115,"count":116,"share":93},"Eli Lilly",108,{"name":118,"count":119,"share":43},"Novo Nordisk",84,{"name":121,"count":122,"share":44},"AstraZeneca",17,{"name":124,"count":122,"share":44},"Bristol Myers Squibb",{"name":126,"count":47,"share":44},"Bayer",{"name":128,"count":29,"share":44},"Sanofi",{"name":130,"count":131,"share":51},"Boehringer Ingelheim",9,{"name":133,"count":54,"share":51},"Abbott",{"name":135,"count":54,"share":51},"Merck",{"name":137,"count":54,"share":51},"Pfizer",[139,148,154,160,168,174,180,187,195,203,209,215],{"title":140,"drug":141,"company":144,"phase":145,"disease":84,"finding":146,"url":147},"Oral small-molecule GLP-1 RA HRS-7535 as monotherapy in Chinese adults with early type 2 diabetes: the OUTSTAND-1 Phase 3 trial",{"name":142,"slug":143},"HRS-7535","hrs-7535",null,"Phase 3","At week 32, HRS-7535 reduced HbA1c from baseline by 1.40% (30 mg), 1.48% (60 mg), and 1.68% (90 mg) versus 0.06% with pbo (placebo-adjusted differences: −1.34%, −1.42%, and −1.62%, respectively; all p\u003C0.0001) based on the efficacy estimand.","https:\u002F\u002Feasddistribute.m-anage.com\u002Ffrom.storage?image=DRQMKAdip9FzW2MCANbX4-3I_BJWtarPUNv7y-ifJF6E4ul5EpwjrIm80CU3rOBC0",{"title":149,"drug":150,"company":115,"phase":145,"disease":84,"finding":152,"url":153},"Efficacy and safety of orforglipron vs placebo added to titrated insulin glargine in adults with long-standing type 2 diabetes: ACHIEVE-5",{"name":151,"slug":151},"orforglipron","An HbA1c \u003C7% (53 mmol\u002Fmol) was reached by 61% (3 mg), 81% (12 mg) and 69% (36 mg) of OFG-treated participants vs 24% in PBO (p\u003C0.001).","https:\u002F\u002Feasddistribute.m-anage.com\u002Ffrom.storage?image=DRQMKAdip9FzW2MCANbX48cGZBu79Lxl5kCk7jPHq9O4bfKKUWwREnHFC7YyQCoe0",{"title":155,"drug":156,"company":115,"phase":145,"disease":84,"finding":158,"url":159},"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist in patients with type 2 diabetes treated with diet and exercise alone (TRANSCEND-T2D-1)",{"name":157,"slug":157},"retatrutide","The estimated mean change from BL in HbA1c was -1.7% (-18.5 mmol\u002Fmol) with 4 mg, -2.0% (-22.0 mmol\u002Fmol) with 9 mg, and -1.9% (-21.0 mmol\u002Fmol) with 12 mg retatrutide, compared to -0.8% (-8.5 mmol\u002Fmol) with placebo (all p\u003C0.001).","https:\u002F\u002Feasddistribute.m-anage.com\u002Ffrom.storage?image=DRQMKAdip9FzW2MCANbX48lCqe_Td0MbhOVhKaojtN9Tpcg5ri0GaDWwOZKb-SxS0",{"title":161,"drug":162,"company":165,"phase":145,"disease":84,"finding":166,"url":167},"Efficacy and safety of TG103 versus dulaglutide as an add-on to metformin in patients with type 2 diabetes: a randomised Phase III trial",{"name":163,"slug":164},"GX-G6","gx-g6","CSPC Pharmaceutical Group","At week 28, HbA1c was reduced by 1.38% in both TG103 15 mg and DULA groups from baseline, and the estimated treatment difference was 0.00% (95%CI: -0.19, 0.18), meeting the prespecified noninferiority criterion (margin 0.4%; one-sided p \u003C 0.0001).","https:\u002F\u002Feasddistribute.m-anage.com\u002Ffrom.storage?image=DRQMKAdip9FzW2MCANbX43gdiAgtbIMAQlA-1CJ5Cmc951RysV2_Bz-KajI1tOGC0",{"title":169,"drug":170,"company":144,"phase":145,"disease":84,"finding":172,"url":173},"Efficacy and safety of anagliptin add-on therapy in patients with type 2 diabetes inadequately controlled by metformin and empagliflozin",{"name":171,"slug":171},"anagliptin","At week 24, the anagliptin group showed a significantly greater reduction in HbA1c compared to the placebo group (mean change: -0.74% ± 0.52 for Anagliptin vs. -0.30% ± 0.60 for placebo; p \u003C 0.001).","https:\u002F\u002Feasddistribute.m-anage.com\u002Ffrom.storage?image=DRQMKAdip9FzW2MCANbX42QswktKR91CerkOUjFRJKLLahKIr0KgWWEmEvMQMqpF0",{"title":175,"drug":176,"company":126,"phase":145,"disease":102,"finding":178,"url":179},"Impact of finerenone on kidney-cardio outcomes by baseline HbA1c levels in a broad chronic kidney disease population: a pooled analysis (INFINITY)",{"name":177,"slug":177},"finerenone","While the risk of serious hyperkalemia was generally higher with finerenone vs placebo, overall incidence was low across HbA1c categories (normoglycemia: 0.6% vs 0.9%; prediabetes: 1.7% vs 0.3%; adequately controlled T2D: 1.0% vs 0.1%; inadequately controlled T2D: 1.1% vs 0.4%).","https:\u002F\u002Feasddistribute.m-anage.com\u002Ffrom.storage?image=DRQMKAdip9FzW2MCANbX41F80glhifKx9JwkX-ZQf9nCFmL-SzOynuTDXmawV7s80",{"title":181,"drug":182,"company":184,"phase":145,"disease":88,"finding":185,"url":186},"Efficacy and safety of olatorepatide, a novel dual-biased GLP-1\u002FGIP receptor agonist in Chinese adults with overweight or obesity: a randomised, double-blind, placebo-controlled, phase 3 study",{"name":183,"slug":183},"olatorepatide","Hansoh Pharmaceutical Group","Pts receiving Olatorepatide 5 mg, 10 mg, or 15 mg compared with pbo had greater achievement of BW reductions of ≥5% (83.5%, 96.1%, 93.9% vs 31.0%), ≥10% (58.9%, 87.4%, 86.4% vs 15.0%), and ≥15% (31.8%, 57.4%, 67.3% vs 3.2%).","https:\u002F\u002Feasddistribute.m-anage.com\u002Ffrom.storage?image=DRQMKAdip9FzW2MCANbX42KEH19xKf15Y-aNikyVoNY2Z5A4ElD0cX3mJE40vTH_0",{"title":188,"drug":189,"company":192,"phase":145,"disease":88,"finding":193,"url":194},"Efficacy and safety of HDM1702 vs. semaglutide (Wegovy®) in patients with obesity: a randomised, open-label, bioequivalence Phase 3 trial",{"name":190,"slug":191},"HDM1702","hdm1702","Hangzhou Zhongmei Huadong Pharmaceutical","The incidence of treatment-emergent adverse events (TEAEs) for HDM1702 and reference semaglutide was 86.6% and 85.7%, respectively.","https:\u002F\u002Feasddistribute.m-anage.com\u002Ffrom.storage?image=DRQMKAdip9FzW2MCANbX45CVPfoUa5lPtXqTa1Ia8KFfoIhyqdYyqpV3Y0HdEVf20",{"title":196,"drug":197,"company":200,"phase":145,"disease":84,"finding":201,"url":202},"Ultra-rapid THBD0206 injection (BioChaperone Lispro, BCLIS) improves postprandial and daily glucose control vs lispro (LIS) in Chinese patients with type 2 diabetes",{"name":198,"slug":199},"BioChaperone Lispro","biochaperone-lispro","Adocia","Non inferiority was confirmed for the primary endpoint for BCLIS: A1C was reduced by 0.65% (BCLIS) and 0.57% (LIS): estimated treatment difference of -0.07% [95% CI -0.18; 0.03].","https:\u002F\u002Feasddistribute.m-anage.com\u002Ffrom.storage?image=DRQMKAdip9FzW2MCANbX4-MSLVo2QWoao_F0KDkLbGRVoim_VyHI3wB65pizcsGt0",{"title":204,"drug":205,"company":118,"phase":145,"disease":88,"finding":207,"url":208},"Impact of cagrilintide 2.4 mg on physical function: post-hoc patient-reported outcomes from REDEFINE 1",{"name":206,"slug":206},"cagrilintide","Compared with placebo, cagrilintide 2.4 mg significantly reduced body weight (ETD −9.6% [−10.6, −8.5]; p\u003C0.0001) and WHtR (ETD −0.04 [−0.05, −0.03]; p\u003C0.0001).","https:\u002F\u002Feasddistribute.m-anage.com\u002Ffrom.storage?image=DRQMKAdip9FzW2MCANbX4-3Lkbn4x6K4-pXp-MUJNvPirqs6YrtOLKTy-USqk_xV0",{"title":210,"drug":211,"company":118,"phase":145,"disease":88,"finding":213,"url":214},"Blood pressure changes with once-weekly semaglutide 7.2 mg in adults with obesity: post hoc analysis of the STEP UP randomised, controlled trial",{"name":212,"slug":212},"semaglutide","In pts with resistant hypertension, mean SBP changes at week 72 were −7.8, −8.2 mmHg and −4.0 mmHg with semaglutide 7.2 mg, semaglutide 2.4 mg, and placebo, respectively.","https:\u002F\u002Feasddistribute.m-anage.com\u002Ffrom.storage?image=DRQMKAdip9FzW2MCANbX4z8KRFAX4ymQgwXrovE6TXtJsdKoa_Z1hca1dn8YS5za0",{"title":216,"drug":217,"company":144,"phase":219,"disease":84,"finding":220,"url":221},"A phase 2 trial of HDM1005 in participants with type 2 diabetes not controlled with diet\u002Fexercise or metformin",{"name":218,"slug":218},"poterepatide","Phase 2","A significantly higher proportion of participants achieved an HbA1c ≤7.0% with HDM1005 (69.2%, 86.5%, 83.3%, and 86.1%) compared to placebo (25.7%).","https:\u002F\u002Feasddistribute.m-anage.com\u002Ffrom.storage?image=DRQMKAdip9FzW2MCANbX4__nVD_PjV4pQItE9PhJQxLAwyjgEEsBwQBhQExK_BEb0",{"summary":223,"bullets":225},[224],"GLP1R, the most frequent target, accounted for 33% of drug-linked abstracts, up from 27% in 2025. Peptides accounted for 38% of drug-linked abstracts, up from 33% in 2025. Bispecific antibodies (2%) were new to the top modalities compared with 2025.",[226,227,228,229,230],"MR (2% of drug-linked abstracts) and CALCR (1%) were new to the top targets compared with 2025.","Small molecules were the most frequent modality (43%).","Type 2 diabetes mellitus (T2DM) was the most frequent disease (51%).","Eli Lilly had the largest company share (21%).","GIPR accounted for 11% of drug-linked abstracts, up from 7% in 2025.",[232],{"year":233,"abstracts":234},2025,1254,{"previous_year":233,"abstracts":236,"targets":239,"modalities":250,"new_in_top_targets":254,"new_in_top_modalities":255},{"previous":234,"current":13,"change_pct":237,"direction":238},12,"rose",[240,242,243,244,247],{"name":23,"count":24,"share":25,"previous_count":241,"previous_share":99,"direction":238},97,{"name":31,"count":32,"share":33,"previous_count":103,"previous_share":57,"direction":238},{"name":39,"count":40,"share":19,"previous_count":131,"previous_share":51,"direction":238},{"name":27,"count":28,"share":29,"previous_count":245,"previous_share":43,"direction":246},59,"fell",{"name":248,"count":51,"share":249,"previous_count":37,"previous_share":51,"direction":246},"NLRP3",0,[251,252,253],{"name":64,"count":65,"share":66,"previous_count":15,"previous_share":25,"direction":238},{"name":75,"count":40,"share":19,"previous_count":100,"previous_share":4,"direction":238},{"name":72,"count":73,"share":57,"previous_count":17,"previous_share":100,"direction":238},[56,49],[79],[257],{"name":258,"count":24,"share":25,"previous_count":241,"previous_share":99,"direction":238},"GLP-1 receptor drugs",1793970603078]